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Abstract
Background
During radiotherapy unwanted radiation to normal tissue surrounding the tumor triggers sur-
vivorship diseases; we lack a nosology for radiation-induced survivorship diseases that
decrease bowel health and we do not know which symptoms are related to which diseases.
Methods
Gynecological-cancer survivors were followed-up two to 15 years after having undergone
radiotherapy; they reported in a postal questionnaire the frequency of 28 different symptoms
related to bowel health. Population-based controls gave the same information. With a modi-
fied factor analysis, we determined the optimal number of factors, factor loadings for each
symptom, factor-specific factor-loading cutoffs and factor scores.
Results
Altogether data from 623 survivors and 344 population-based controls were analyzed. Six
factors best explain the correlation structure of the symptoms; for five of these a statistically
significant difference (P< 0.001, Mann-Whitney U test) was found between survivors and
controls concerning factor score quantiles. Taken together these five factors explain 42 per-
cent of the variance of the symptoms. We interpreted these five factors as radiation-induced
syndromes that may reflect distinct survivorship diseases. We obtained the following fre-
quencies, defined as survivors having a factor loading above the 95 percent percentile of
the controls, urgency syndrome (190 of 623, 30 percent), leakage syndrome (164 of 623, 26
percent), excessive gas discharge (93 of 623, 15 percent), excessive mucus discharge (102
of 623, 16 percent) and blood discharge (63 of 623, 10 percent).
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Conclusion
Late effects of radiotherapy include five syndromes affecting bowel health; studying them
and identifying the underlying survivorship diseases, instead of the approximately 30
long-term symptoms they produce, will simplify the search for prevention, alleviation and
elimination.
Introduction
When cancer treatment has eliminated the last malignant cell, the long-term unwanted conse-
quences of the treatment, sadly enough, become lifelong threats to the cured cancer survivor’s
health [1]. Concerning cancer situated in the thorax, the threats are handled primarily as a sur-
vivorship disease such as, for example, radiation-induced heart failure or cardiac infarction.
Such an approach has advantages as compared to using single symptoms as an end point in
clinical research [2]. Concerning cancer situated in the pelvic cavity a large number of symp-
toms have been documented as radiation-induced late effects [3]; it is unclear, however, if
these symptoms should be seen as manifestations of one or several survivorship diseases [4–6].
We have no nosology for radiation-induced survivorship diseases and we do not know which
disease decreasing bowel health produces which symptoms. Identifying radiation-induced
syndromes among cancer survivors may give insight into the presence of distinct radiation-
induced survivorship diseases and the symptoms they produce.
Modern cancer treatment clearly differs from that given 50 years ago [7]. Surgical mortality
has declined, e.g. due to anesthesiological achievements and refined surgical techniques. We
now have access to an ever increasing number of cytotoxic drugs and biological response mod-
ifiers [8]. New technology for imaging of the patient and tumor and for administration of ion-
izing radiation has made it possible to dramatically increase the ratio between the dose of
ionizing radiation to the tumor and unwanted doses to surrounding normal tissue during
radiotherapy, an improvement often making it possible to increase doses to the tumor [9]. All
these success stories have produced a historically new situation with a large growth in the
number of aging cancer survivors—probably in the vicinity of 21 million in Europe—as well as
an increasing number of survivors with treatment-induced survivorship diseases that decrease
long-term bowel health.
Possibly we already have the means to prevent, alleviate or eradicate a large part of the sur-
vivorship diseases that decrease bowel health, means including better dose plans, dietary
changes, probiotics or drugs. We just lack the knowledge needed to employ these means satis-
factorily. In our division we have developed clinimetric methods to document patient-reported
long-term symptoms one by one (atomized symptom documentation) [10–13]. These meth-
ods give data sets which can be used to disentangle syndromes that may reflect radiation-
induced survivorship diseases that produce the symptoms. Moreover, during the 1990s and
2000s by and large all patients with cancer in Sweden in a certain geographical region were
treated at the same single clinic for radiotherapy. All residents in Sweden have personal iden-
tity numbers which together with population-based registers makes it easy to identify and
follow up long-term cancer survivors by using postal questionnaires. Together with a literate
and cooperative population we thus have the possibility to retrieve truly population-based
information with high accuracy. Benefiting from this situation, we have retrieved patient-
reported information on 28 long-term gastrointestinal symptoms among gynecological cancer
survivors treated with radiotherapy [14]. Using a novel modification of factor analysis, we here
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disentangle syndromes among these, syndromes that may be related to distinct radiation-
induced survivorship diseases. We also investigate which long-term symptoms to be included
in which syndrome.
Methods
Survivors and controls
Dunberger and co-workers describe the data collection in detail [14–16]. Between 1991 and
2003 altogether 1800 women were treated with external pelvic radiotherapy for a gynecological
malignancy at two clinics in Sweden, by and large corresponding to all relevant patients in two
geographical regions. We excluded survivors born 1927 or earlier and who could not under-
stand Swedish (S1 Fig).
Data collection
Qualitative phase. In semistructured interviews with 23 women, we attempted to docu-
ment all of the symptoms the survivors had at the time. A secretary transcribed the interviews
verbatim, and we sorted the information into groups of statements reflecting specific atomized
long-term symptoms. Based on this, we constructed a study-specific questionnaire with word-
ing as close as possible to those of the survivors. For example, when asking for flatulence we
gave both of the Swedish words corresponding to fart and wind in English. We asked for
occurrence and, selectively, intensity and duration of the symptom [13]. For example, in
answering “Do you have uncontrolled loud wind (fart)” answering categories were “No”, “Yes,
occasionally”, “Yes, at least once a month,” “Yes, at least once a week,” “Yes, at least 3 times a
week,” and “Yes, at least once a day” (a person-incidence scale).
Data collection. All survivors received a letter and a telephone call before we sent out the
questionnaire. Three weeks after posting the questionnaire we sent a thank-you-and-reminder
card and, when appropriate, made reminding telephone calls. All actions were taken by neutral
third-party secretariat [17]; none of the previously involved health-care professionals were
involved or had access to the data.
Ethics statement, as endorsed by the Ethical Review Board, completing the questionnaire
and posting it to us was considered as a written consent of participation. The study was
approved by the Regional Ethical Review Board (2005/1424-31/4), Stockholm, Sweden.
Statistical analysis
Overview. To make the analysis blinded, the two involved statisticians used variable
names such as “V43” with no labels referring to the symptoms during the programming. We
used a modified Exploratory Factor Analysis to define the number of factors that best describe
the correlation matrix of the data, factor loadings, factor-specific cutoffs for factor loadings
and factor scores (for details, please see the statistical appendix S1 File) [18]. Having ordinal
data, we consistently used Spearman’s rank correlation coefficient as input to the Exploratory
Factor Analysis. Parameters were estimated using maximum likelihood estimation [19].
Number of factors. In an effort to avoid over- and underestimation of the optimal num-
ber of factors, we used Parallel analysis with 10 000 permutations of the data as well as a ver-
sion of Kaiser’s rule, based on 10 000 non-parametric bootstrap estimates [20–22]. Both
methods are based on an investigation of eigenvalues of the estimated data correlation matrix.
Factor-specific factor-loading cutoffs. We formulated a tailor-made method for setting
factor-specific cutoffs. We evaluated this method and made decisions on parameter values
based on simulated data from nine distributions of known factor structures.
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Factor-score comparison. We compared quantiles of the factor scores of the survivors
and population controls. The factor scores were calculated using only symptoms with factor
loadings greater in magnitude than the previously determined factor-specific factor-loading
cut-offs. First the two data sets were imputed using mode imputation. The imputed data sets
were then combined into one data set that was standardized and the survivor-specific factor
scores were calculated as linear combinations of the observations for the survivor and the fac-
tor-loadings associated with a specific factor that were larger in magnitude than the factor-spe-
cific cutoff. We finally compared, for each factor, the factor-score quantiles of the survivors
and the population controls using the Mann-Whitney U test.
Results
As seen in the flow chart (S1 Fig), 650 (79%) of 823 eligible gynecological-cancer survivors and
344 (72%) of 478 eligible matched population-based controls returned a questionnaire. Of the
gynecological-cancer survivors we excluded seven with missing information on more than 30
percent of the 28 variables reflecting long-term symptoms and 20 having a bowel stoma, leav-
ing us with 623 survivors for the present analysis. Table 1 shows that most survivors were in
the age 60 to 69 category, 63 percent were married or had a partner and 30 percent had a uni-
versity education. A coding error made the population controls on average younger than the
survivors; the difference in mean age was 6.2 years. Any relation between age and symptom
occurrence among the population-based controls (data not shown) is weak if at all present.
Number of factors
The optimal number of factors was estimated to be six both when we used Parallel analysis and
a bootstrap version of Kaiser’s rule (Fig 1 and data in statistical appendix S1 File) [23].
Symptoms included in each factor
In Table 2 the varying cut-offs for the factor loadings across the six factors are presented along
with the factor loading for each symptom and factor. Since each factor is regarded as a syn-
drome that may reflect a distinct survivorship disease (with the long-term symptoms being
seen as manifestations of the disease), we in Table 2 describe the factors as urgency syndrome,
leakage syndrome, constipation, excessive gas discharge, excessive mucus discharge and blood dis-
charge. The factors in Table 2 and Figs 2 and 3 are ordered according to the proportion of vari-
ance in the data that is explained. Fig 2 shows a graphical view of the symptoms having factor
loadings above the factor-specific factor-loading cutoffs. The bars represent the value of the
factor loading (and do not represent a confidence interval)–the broader the bar is, the greater
the proportion of the variance of the symptom the specific factor explains. Thirteen of the 28
symptoms loaded onto two or more factors.
Comparison between survivors and controls
Fig 3 shows that being a survivor is associated with five of the factors but not with the factor
cited as constipation. Notwithstanding that, the symptoms loading onto this factor may have
different causes in survivors and population-based controls, we thus have no data to support
the belief that constipation is a syndrome related to a survivorship disease.
Classifying a survivor as having a specific syndrome with a factor loading above that of the
95 percentile among the controls, we obtained the following numbers: urgency syndrome (190
of 623, 30 percent), leakage syndrome (164 of 623, 26 percent), excessive gas discharge (93 of
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Table 1. Certain characteristics for 623 gynecological-cancer survivors and 344 population-based controls.
GYNECOLOGICAL CANCER SURVIVORS (N = 623) AND CONTROLS (N = 344)
No. (%) No. (%)
Survivors Controls Survivors Controls
Age at follow-up*—years Pelvic floor injuryT,£
-49 66 (11) 102 (30) Yes 111 (17) 101 (29)
50–59 100 (16) 80 (23) Not stated 14 (2) 2 (1)
60–69 245 (40) 78 (23) Intercurrent diseases£
70- 212 (33) 82 (24) Previous abdominal surgery 253 (41) 156 (45)
Not stated 0 (0) 2 (1) Not stated 31 (5) 0 (0)
Marital status Diabetes mellitus 54 (9) 17 (5)
Married or living with partner 355 (57) 220 (64) Not stated 5 (1) 6 (2)
Widow 81 (13) 37 (11) Hypertension 220 (35) 91 (27)
Has partner but lives alone 36 (6) 22 (6) Not stated 13 (2) 3 (1)
Single 149 (24) 65 (19) Heart failure 32 (5) 8(2)
Not stated 2 (0) 0 (0) Not stated 13 (2) 3 (1)
Education Angina pectoris 32 (5) 11 (3)
Elementary school 194 (31) 69 (20) Not stated 13 (2) 3 (1)
Secondary school 238 (38) 146 (42) Cardiac infarction 18 (3) 5 (2)
College or university 190 (30) 127 (37) Not stated 13 (2) 3 (1)
Not stated 1 (0) 2 (1) Crohn’s disease treatment 1 (0) 0 (0)
Employment Not stated 18 (3) 12 (4)
Student 6 (1) 2 (1) Ulcerative colitis 4 (1) 7 (2)
Unemployed 14 (2) 6 (2) Not stated 33 (5) 17 (5)
Employed 204 (33) 188 (55) IBSP  treatment 23 (4) 13 (4)
Housewife, other 12 (2) 5 (2) Not stated 20 (3) 12 (4)
On sick leave 11 (2) 10 (3) Hemorrhoids treatment 57 (9) 45 (13)
Disability pension 55 (9) 15 (4) Not stated 24 (4) 22 (6)
Retired 318 (51) 117 (34) Lactose intolerance 34 (5) 13 (4)
Not stated 3 (0) 1 (0) Not stated 15 (2) 13 (4)
Country of birth Gluten intolerance 9 (1) 3 (1)
Sweden 514 (83) 316 (92) Not stated 9 (1) 14 (4)
Other country 107 (17) 28 (8) Pelvic organ prolapse 13 (2) 13 (4)
Not stated 2 (0) 0 (0) Not stated 17 (3) 12 (4)
Place of residency Rheumatism 40 (6) 19 (6)
Rural district 58 (9) 34 (10) Not stated 13 (2) 3 (1)
Village/Small town 193 (31) 93 (27) Kidney disease 19 (3) 8 (2)
> 500.000 citizens 371 (60) 214 (62) Not stated 13 (2) 3 (1)
Not stated 1 (0) 3 (1) Lung disease 37 (6) 12 (4)
Smoking Not stated 13 (2) 3 (1)
Current smoker 143 (23) 88 (26) Thrombosis 46 (7) 16 (5)
Former smoker 191 (31) 108 (31) Not stated 13 (2) 3 (1)
Never smoker 281 (45) 147 (43) Osteoporosis 59 (9) 25 (7)
Not stated 8 (1) 1 (0) Not stated 13 (2) 3 (1)
Body Mass Index Psychological disorders 79 (13) 43 (13)
18.5 17 (3) 5 (2) Not stated 13 (2) 3 (1)
18.5–25 270 (43) 163 (47) Neurological disorders 15 (2) 3 (1)
25–30 199 (32) 116 (34) Not stated 13 (2) 3 (1)
30 99 (16) 43 (13) Joint disorder 171 (27) 95 (28)
(Continued )
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623, 15 percent), excessive mucus discharge (102 of 623, 16 percent) and blood discharge (63 of
623, 10 percent).
Discussion
Using a population-based setting for identifying and retrieving patient-reported information
from cancer survivors, we previously have found that gynecological-cancer survivors three to
15 years after radiotherapy have 28 different gastrointestinal symptoms [14]. Applying a modi-
fied factor analysis, and comparing with population controls, our results indicate that these 28
symptoms may be seen as five syndromes that may be manifestations of five different radia-
tion-induced survivorship diseases causing a decrease in bowel health.
Table 1. (Continued)
GYNECOLOGICAL CANCER SURVIVORS (N = 623) AND CONTROLS (N = 344)
No. (%) No. (%)
Survivors Controls Survivors Controls
Not stated 38 (6) 17 (5) Not stated 13 (2) 3 (1)
Exercise Medication
Never 72 (12) 20 (6) Using any kind of medication 440 (71) 194 (56)
At least once a month 84 (13) 59 (17) Not stated 8 (1) 6 (2)
At least once a week 450 (72) 262 (76) Estrogen 226 (36) 50 (15)
Not stated 17 (3) 3 (1) Not stated 10 (2) 5 (2)
Parity Diagnosis
Never given birth 156 (25) 45 (13) Sarcoma uteri 30 (5)
1–3 Children 418 (67) 280 (81) Vulvar cancer 6 (1)
> 3 Children 49 (8) 19 (6) Vaginal cancer 14 (2)
Not stated 0 (0) 0 (0) Cervical cancer 146 (23)
Delivery£ Endometrial cancer 363 (58)
Fast (< 5h) 252 (40) 147 (43) Ovarian cancer 50 (8)
Slow (> 24 h) 139 (22) 88 (26) Fallopian tube cancer 14 (2)
Vacuum 41 (7) 43 (13) Not stated 0 (0)
Forceps 11 (2) 7 (2) Treatment modality
Episiotomy 133 (21) 117 (34) Surgery + EBRT‡ 47 (8)
Caesarean 28 (4) 40 (12) Surgery + EBRT‡ + BT¥ 338 (54)
Breech birth 19 (3) 20 (6) Surgery + EBRT‡ + Chemo# 64 (10)
Not statedΩ 7 (1) 2 (1) Surgery + EBRT‡ + BT¥ + Chemo# 113 (18)
Child weight at delivery EBRT‡ 2 (0)
> 4 kg, 1 child 79 (13) 54 (16) EBRT‡ + BT¥ 27 (4)
> 4 kg, 2 children 44 (7) 29 (8) EBRT‡ + Chemo# 8 (1)
Not stated 4 (1) 261 (76) EBRT‡ + BT¥ + Chemo# 23 (4)
Anal injuryT,£ Not stated 1 (0)
Yes 18 (3) 18 (5)
Not stated 19 (3) 2 (1)
*Approximate age at follow up. Calculated as 2006 –year of birth.
£Only dichotomous variables in this category. The numbers of negative values are left out.
ΩNumber of survivors for which no information was recorded regarding the delivery variables.
TInjury inflicted during delivery or at other occasion. IBSP  denotes Irritable Bowel Syndrome.
EBRT‡ denotes External Beam Radiation Therapy. BT¥ denotes Brachy Therapy. Chemo# denotes Chemotherapy
doi:10.1371/journal.pone.0171461.t001
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Technically speaking, the first step in the analyses we performed answered the question
“How many factors can be disentangled [20]? In the second step we sought to determine
which estimated factor loadings reflect non-zero population factor loadings. The initial identi-
fication of six factors was done with two different methods [21]. This observation is thus
robust. However, a number of cautions indicate that six may not be the exact number in real
life. Although we, during a meticulous qualitative phase, interviewed survivors and experts to
search for all manifestations of survivorship diseases occurring among gynecological cancer
survivors, we may have missed key symptoms. Moreover, despite repeated face-to-face
Fig 1. The estimated factor loadings onto the six factors after the Varimax rotation was performed. Factor loadings are colored according to
factor affiliation and are connected by solid lines of the corresponding color. Dashed horizontal lines correspond to the factor specific cutoffs suggested
by the Variable Cutoff Method. Crosses of a specific color correspond to factor loadings strictly greater in magnitude than the cutoff of the same color
whereas solid dots of a specific color correspond to factor loadings smaller in magnitude than the cutoff of the corresponding color. Using the Variable
Cutoff Method 10000 parametric bootstrap estimates of the factor loadings were calculated and 0,0.01,. . .,0.99,1 were used as candidate cutoffs.
doi:10.1371/journal.pone.0171461.g001
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Table 2. Estimated factor loading structure and factor model properties.
SYMPTOM INCIDENCE ESTIMATED FACTOR LOADINGS¥
Number of events/
Total number of
individuals¤
URGENCY
SYNDROME
LEAKAGE
SYNDROME
CONSTIPATION EXCESSIVE GAS
DISCHARGE
EXCESSIVE
MUCUS
DISCHARGE
BLOOD
DISCHARGE
Controls Survivors Cutoff†
(%) (%) 0.21 0.32 0.21 0.39 0.39 0.14
82/344 308/616
Loose stools* (24) (50) 0.71 0.15 -0.02 0.07 0.13 0.02
Leakage of loose
stools
3/344 52/620
while awake* (1) (8) 0.40 0.62 -0.02 0.09 0.26 0.12
Leakage of loose
stools
3/343 13/623
while asleep* (1) (2) 0.22 0.53 0.11 0.06 0.21 0.01
Hard stools that
are difficult to
48/343 75/619
pass* (14) (12) -0.06 0.10 0.76 0.08 0.05 0.03
Need to strain
with defecation
28/337 54/615
at least half of
the time
(8) (9) -0.05 0.10 0.80 0.06 0.00 0.02
Leakage of solid
stools
1/344 11/620
while awake* (0) (2) 0.04 0.43 0.09 0.10 0.02 0.00
Leakage of solid
stools
0/344 4/623
while asleep* (0) (1) 0.00 0.34 0.10 0.04 0.00 0.04
Involuntary
unspecified
48/343 166/620
flatulence* (14) (27) 0.25 0.18 0.15 0.79 0.13 0.05
33/344 134/621
Involuntary loud
flatulence*
(10) (22) 0.20 0.18 0.15 0.81 0.09 0.05
Involuntary foul-
smelling
33/343 156/618
flatulence* (10) (25) 0.27 0.21 0.16 0.67 0.09 0.09
104/342 198/617
Abdominal
bloating*
(30) (32) 0.32 0.09 0.39 0.30 0.20 0.09
Stools containing
excessive
9/343 66/618
amounts of
mucus *
(3) (11) 0.21 0.02 0.22 0.09 0.70 0.08
Anal leakage of
mucus
5/343 31/618
while awake* (1) (5) 0.11 0.18 0.07 0.11 0.81 0.18
Anal leakage of
mucus
1/344 7/620
while asleep* (0) (1) 0.07 0.26 0.06 0.07 0.51 0.05
Stools containing
excessive
6/341 27/617
amounts of
blood*
(2) (4) 0.15 0.08 0.24 0.03 0.13 0.53
(Continued)
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Table 2. (Continued)
SYMPTOM INCIDENCE ESTIMATED FACTOR LOADINGS¥
Number of events/
Total number of
individuals¤
URGENCY
SYNDROME
LEAKAGE
SYNDROME
CONSTIPATION EXCESSIVE GAS
DISCHARGE
EXCESSIVE
MUCUS
DISCHARGE
BLOOD
DISCHARGE
Controls Survivors Cutoff†
(%) (%) 0.21 0.32 0.21 0.39 0.39 0.14
Anal leakage of
blood
1/343 12/620
while awake* (0) (2) 0.08 0.13 0.07 0.08 0.15 0.97
Anal leakage of
blood
0/343 0/621
while asleep* (0) (0) 0.00 0.04 0.00 0.02 0.02 0.40
Sensation of not
having emptied
39/340 110/619
after defecation* (11) (18) 0.19 0.11 0.55 0.14 0.17 0.10
Need to repeat
defecation within
32/341 204/619
one hour* (9) (33) 0.61 0.16 0.19 0.17 0.19 0.06
Sudden
defecation
urgency
33/341 245/616
requiring
lavatory*
(10) (40) 0.85 0.18 0.08 0.19 0.10 0.06
Inability to hold
stools for >5
40/344 269/615
minutes during
urgency‡
(12) (44) 0.69 0.21 0.10 0.14 0.04 0.06
17/341 146/620
Immediate need
to defecate*
(5) (24) 0.74 0.25 -0.04 0.22 0.03 0.07
Fecal leakage
without warning
3/344 52/620
despite previous
defecation*
(1) (8) 0.35 0.68 0.02 0.11 0.19 0.12
Defecation into
clothing without
3/344 18/621
forewarning* (1) (3) 0.26 0.47 0.02 0.07 0.03 0.16
29/343 56/621
Anal itching* (8) (9) 0.23 0.12 0.26 0.11 0.07 0.15
12/343 32/621
Anal pain* (3) (5) 0.22 0.12 0.28 0.09 0.13 0.14
28/340 112/616
Abdominal pain* (8) (18) 0.34 0.10 0.31 0.16 0.16 0.07
5/340 21/619
Self-perception
of fecal odor*
(1) (3) 0.19 0.52 0.14 0.21 0.14 0.05
ESTIMATED FACTOR MODEL PROPERTIES
Sum of squares
of loadings
3.7 2.4 2.2 2.1 1.8 1.6
Proportion of variance explained 0.13 0.09 0.08 0.08 0.06 0.06
(Continued)
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validation we may have missed key variations in the wording used to identify each of the dif-
ferent symptoms; this error may turn up as varying degrees of sensitivity and specificity in
identifying different symptoms during the data collection. All these weaknesses may have com-
promised our ability to disentangle additional factors that may be captured in a new data
collection.
In comparing factor-score quantiles of the cancer survivors and population controls, we
found a statistically significant difference for five of the six identified factors. Thus, in the
application of these statistical parameters to the real world, we consider the five factors as five
distinct treatment-induced survivorship syndromes. We have no biological data from the sur-
vivors; for example, we have no tests in the blood or feces for markers indicating inflammatory
processes or fibrosis. We are not aware of any previous effort similar to ours in identifying sur-
vivorship syndromes. Nevertheless, based on biological, physiological and medical facts pre-
sented in the S1 Table we label the five syndromes leakage syndrome, urgency syndrome,
excessive mucus discharge, excessive gas discharge and blood discharge. The initiation of the sur-
vivorship diseases, manifested by these syndromes, results when unwanted ionizing radiation
reaches the anal-sphincter region, the rectum, the sigmoid, the small bowel and possibly also
other volumes of normal tissue in the pelvic cavity (S2 Fig). These disease labels are prelimi-
nary as are the designations of the organs involved and the mechanisms.
When we varied the details of the factor analysis, fine-tuning which variables to include in a
certain factor, e.g., by making varying assumptions for the determination of cut-offs, we pro-
duced somewhat different results (data not shown). In the interpretation we thus have a varia-
tion in the degree of evidence for which symptoms to include in one of the identified
syndromes. But some clear distinctions can be made. No analysis, for example, produced a
result in which the three symptoms included in excessive mucus discharge loaded in the factor
interpreted as urgency syndrome. Results thus clearly indicate these mucus-related symptoms
are produced by processes other than the processes giving the symptoms in urgency syndrome.
Concerning the pathophysiology, we know little about the processes that ultimately pro-
duced the symptoms included in respective syndrome. Probably endothelial damage in
Table 2. (Continued)
SYMPTOM INCIDENCE ESTIMATED FACTOR LOADINGS¥
Number of events/
Total number of
individuals¤
URGENCY
SYNDROME
LEAKAGE
SYNDROME
CONSTIPATION EXCESSIVE GAS
DISCHARGE
EXCESSIVE
MUCUS
DISCHARGE
BLOOD
DISCHARGE
Controls Survivors Cutoff†
(%) (%) 0.21 0.32 0.21 0.39 0.39 0.14
Cumulative proportion of variance
explained#
0.13 0.22 0.3 0.38 0.44 0.5
¥Estimated factor loadings greater than the corresponding cutoff produced by the Variable Cutoff Method are presented in bold font.
¤The denominators deviate from 344 (the number of controls) and 623 (the number of survivors) due to missing values.
†Cutoffs on estimated factor loadings produced by the Variable Cutoff Method.
*At least once a month.
+In the Factor analysis all categories (“No, not at any occasion”, “Yes, more seldom than at half of the occasions when I have defecated”, “Yes, more often
than at half of the occasions”, “Yes, at every occasion”) were used. Cutoff used for frequencies in the second and third columns.
‡In the Factor analysis all categories (”Not appropriate, I have not had any urgency”,”Shorter than 1 minute”,”Between 1 and 5 minutes”,”Between 1 and 30
minutes”,”30 minutes or longer”) were used. Cutoff used for frequencies in the second and third columns.
#Cumulative sum of the proportions of variance explained. The cumulative sum of a vector v = (a1, a2, a3,. . ., an) is defined as v’: = (a1, a1+ a2, a1+ a2
+ a3,. . ., a1 + a2+ a3 +. . .+ an)
doi:10.1371/journal.pone.0171461.t002
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Fig 2. The result of applying the cutoffs suggested by the Variable Cutoff Method to the estimated factor loadings onto the six
factors. Dots correspond to factor loadings that are strictly greater in magnitude than the factor specific cutoff. Lines through the dots
correspond to the magnitude of the specific factor loadings and are presented for comparison purposes only with the aim of identifying the
variables that most heavily load onto a specific factor and thus to aid interpretation. The plot illustrates how cutoffs on factor loadings ease the
interpretation of the factor loading structure produced by EFA. Several factor loadings are discarded by the Variable cutoff method. Based on
this reduced factor loading structures the six factors were interpreted as: Urgency syndrome (red), Leakage syndrome (green), Constipation
(dark blue), Excessive gas discharge (light blue), Excessive mucus discharge (magenta), Blood discharge (black).
doi:10.1371/journal.pone.0171461.g002
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Fig 3. Comparisons between estimated factor score quantile positions of survivors and controls for the six factors. The 0.25, 0.5
(median), 0.75, 0.9 and 0.95 sample quantiles are presented. Scores were calculated based on the reduced factor loading structure. Prior to
calculating scores a simple mode imputation was performed. Further Mann-Whitney p-values were calculated and are presented to the left
in the figure. Except in the case of the constipation factor, the factor scores of the treated population were found to be distributed
significantly differently from the scores of the non-treated population. Clearly, in all cases where these distributions differ, the scores of the
survivors tend to be larger than the scores of the controls.
doi:10.1371/journal.pone.0171461.g003
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capillaries in the gut wall attracts white blood cells; they may aggregate causing hypoxia and
later ischemia. We believe inflammatory and fibrotic processes in the gut wall, as well as stem-
cell depletion, play a role. Possibly changes in the wall of the small bowel, proximal colon, dis-
tal colon (sigmoid colon) and rectum are related to varying symptoms. Excessive gas discharge
and excessive mucus discharge probably are related to a changed composition and function of
the gut microbiota, and we know the microbiota interacts with the gut wall. Endoscopically, in
survivors with blood discharge, one can inspect a gut wall exclusively comprised of connective
tissue, with telangiectasia and ulcerations that bleed on the surface. Fibrotic muscle in the
internal and external anal sphincters probably explains leakage-related symptoms, but some
symptoms in the leakage syndrome may also reflect increased pressure on the sphincters. Gall
salt malabsorption, and bacterial overgrowth from the colon to the small bowel are well recog-
nized clinically but we have no data to relate these phenomena to the syndromes we identified.
If a relation exists between age and symptom occurrence among the population-based con-
trols, it is weak at most. That the controls are younger than the cancer survivors probably does
not spuriously affect the conclusion that one of the six identified syndromes is not radiation-
induced.
Lacking a basic understanding of how different pathophysiological processes in different
parts of the abdomen and gut can be linked to the syndromes we identified (or to single symp-
toms), it is too early to suggest a nosology for the survivorship diseases decreasing bowel
health. This study only concerns females; in males (prostate-cancer survivors) a corresponding
factor analysis resulted in four syndromes that may be cited as leakage syndrome, urgency syn-
drome, excessive mucus discharge and excessive gas discharge/abdominal pain [24]. That is, in
that population, four of the five syndromes we identified were disentangled and the data indi-
cate the same survivorship diseases affect men and women concerning the bowel. Possibly
new factor analyses on already collected material can give us more information. Combining
the loading factor for each symptom with symptom frequency we get a metric (factor score) of
the intensity of the syndrome. Using this metric we can investigate different effects of the five
syndromes on factors such as dose to different risk organs, smoking, time since treatment and
diet—investigating whether the syndromes may manifest different pathophysiological pro-
cesses. Such a metric of the intensity of a syndrome may assist the search for preventive mea-
sures. Toxicity scores and quality-of-life instruments may introduce a noise when symptoms
from different syndromes are combined. Such instruments may mix symptoms from different
syndromes that reflect different pathophysiological processes. If for example, a genetic factor,
or dose to a specific risk organ, is studied, the noise may be reduced if symptoms related to the
effect (a pathophysiological process) by the gene or the dose can be studied separately. Con-
cerning today’s survivors, time will show if we can get sharper diagnostic tools and better treat-
ments if we combine the identification of syndromes with tests in the blood and feces, and
possibly also endoscopic studies and X-rays, to specific survivorship diseases for which we
develop prevention, alleviation and treatments.
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